Application of withaferin A in preparation of medicament for preventing or treating glioblastoma

A technology of glioblastoma, withaferin, applied in the field of antitumor drugs

Inactive Publication Date: 2019-10-11
INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] So far, it has not been reported that withaferin A induces the apoptosis of glioblastoma by up

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of withaferin A in preparation of medicament for preventing or treating glioblastoma
  • Application of withaferin A in preparation of medicament for preventing or treating glioblastoma
  • Application of withaferin A in preparation of medicament for preventing or treating glioblastoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] (1) Dilute withaferin with the DMEM high-sugar culture medium containing 10% fetal bovine serum, 100kU / L penicillin, and 100mg / L streptomycin to be the concentration of Table 1 respectively, and different concentrations of withaferin A act respectively Cell viability of U251-MG cells after 12, 24 and 48 hours see figure 1 and Table 1.

[0038] Table 1 Cell survival rate of withaferin A acting on U251-MG for different time at different dosages

[0039]

[0040] It can be seen that withaferin A inhibits the proliferation of glioblastoma U251-MG in a concentration- and time-dependent manner, and the half maximal inhibitory concentration (IC 50 ) is about 1.37 μΜ.

[0041] Dilute withaferin with 10% fetal bovine serum, 100kU / L penicillin, and 100mg / L streptomycin in DMEM high-sugar medium, respectively, to the concentrations shown in Table 2. Different concentrations of withaferin A act on U251-MG respectively. The cell apoptosis rate after 12, 24 and 48 hours see fig...

Embodiment 2

[0053] (1) Dilute withaferin with the DMEM high-sugar culture medium that contains 10% fetal bovine serum, 100kU / L penicillin, 100mg / L streptomycin to be the concentration of table 4 respectively, different concentrations of withaferin A act respectively Cell viability of U251-MG cells after 12, 24 and 48 hours see Image 6 and Table 4.

[0054] Table 4 The cell survival rate of withaferin A acting on U87-MG for different time at different dosages

[0055]

[0056] It can be seen that withaferin A inhibits the proliferation of glioblastoma U87-MG in a concentration- and time-dependent manner, and the half maximal inhibitory concentration (IC 50 ) is about 3.46 μΜ.

[0057] Dilute withaferin with 10% fetal bovine serum, 100kU / L penicillin, 100mg / L streptomycin DMEM high-sugar culture medium respectively to the concentration of table 5, different concentrations of withaferin A act on U87-MG respectively The cell apoptosis rate after 12, 24 and 48 hours see Figure 7 and T...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Half inhibitory concentrationaaaaaaaaaa
Half inhibitory concentrationaaaaaaaaaa
Login to view more

Abstract

The invention relates to an anti-tumor medicament prepared for treating glioblastoma. The medicament refers to withaferin A, realizes the activity of resisting glioblastoma by inducing apoptosis, induces apoptosis of glioblastoma through a mitochondrial pathway, and activates the mitochondrial apoptosis pathway by upregulating the protein content of Bad and Bim.

Description

technical field [0001] The invention relates to an antitumor drug, in particular to withaferin A and its application in the preparation of drugs for preventing or treating glioblastoma. Background technique [0002] Glioma refers to tumors originating from glial cells and is the most common primary intracranial tumor, accounting for 32% of all primary central nervous system tumors and 81% of central nervous system malignant tumors. Glioblastoma (GBM) is the most malignant (WHO grade IV) and most aggressive glioma. It has the highest incidence rate among primary malignant central nervous system tumors, accounting for about 46.1%. TMZ concurrent radiotherapy combined with adjuvant chemotherapy is the standard treatment for malignant glioma, but it can only increase the 2-year survival rate from 10.4% to 26.5%, and the median survival time does not exceed 15 months, and drug resistance will occur. Therefore, it is extremely important to seek new drugs, new targets and new mech...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/585A61P35/00
CPCA61K31/585A61P35/00
Inventor 王金华唐琴庞晓丛李婉富炜琦郑湘锦杜冠华
Owner INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap